ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATION CONFLICTS WITH BANNED DRUG LIST ENTRIES
Corrigan, B. (2003). Attention deficit hyperactivity disorder in sport: A review. International Journal of Sports Medicine, 24, 535-540.
Attention deficit hyperactivity disorder (ADHD) is a controversial problem in sport since participants with this disorder often require banned stimulant medication while competing. Little information is available in the literature concerning this problem or whether sports people should be allowed to participate while on stimulant therapy. This brief review of recent findings in ADHD (Medline from the years 1980 to 2002), especially as they apply to sport, suggests some guidelines that could be applied by sporting bodies to allow ADHD sufferers to compete. Recent scientific evidence, clinical, genetic, and imaging techniques, confirm that ADHD is characterized by dysfunction in dopamine transmission in the frontal lobes and basal ganglia structures, regions associated with attention and behavior. The dopamine transporter (DAT) regulates dopamine by removing excess. In ADHD people, the number and density of DATs and DAT binding sites are increased by up to 70 %. The dopamine agonist methylphenidate blockades DAT, significantly increasing extra cellular dopamine, so correcting the dopamine deficiency.
Implication. Although there are problems with their use as far as the International Olympics Committee (IOC) is concerned, it would seem most unfair to penalize sports people by having to give up their medication, even for a few days or at some arbitrary age, in order to compete.
Return to Table of Contents for this issue.